Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2016

View Archived Issues

Vyriad enters global license agreement with Stinginn

Eisai reviews accomplishments of first quarter of fiscal 2016

Merck & Co. patents BACE1 and -2 inhibitors

Sumitomo Dainippon Pharma discloses Nav1.7 channel blockers

Millennium Pharmaceuticals describes Nampt inhibitors

Scripps Research Institute develops MCT1 and/or MCT4 inhibitors

MyoKardia presents cardiac myosin activators

MMRF and University of Michigan collaborate on a new molecular profiling initiative

Autologous BMC is safe and effective in treating patients with atrophic non-unions

FDA accepts Merck & Co.'s MK-1293 NDA for review

Mylan completes public offer settlement with Meda

CheckMate 026 phase III study of Opdivo does not meet primary endpoint

ZSYM73 affibody in a mouse model of AD

Shire reports recent developments of second quarter 2016

UT Southwestern receives funding from NCI to target rising rates of kidney cancer

Hematogenix announces launch of Ventana PD-L1 (SP142) and (SP263) assays

FDA approves Merck & Co.'s Keytruda for patients with recurrent or metastatic HNSCC

Lantern Pharma to evaluate BioNumerik's Tavocept

FDA grants orphan drug designation to vedolizumab

Boehringer Ingelheim begins phase II trial of BI-425809 in patients with schizophrenia

Phase II trial of volixibat in patients with NASH recruiting patients

Tolerogenic nanoparticles improve biologic drug efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...